Defined synthetic vaccines.
Although vaccines have proven very successful in preventing certain infectious diseases, progress in the field has been slowed by the tediousness of developing classical vaccines consisting of whole pathogens. Thus, there is great need for improvement in several areas: firstly, the range of diseases which can be treated has to be expanded. Secondly, antigens have to be defined to make the use of whole pathogens as antigen obsolete. And thirdly, new adjuvants have to be developed which show low toxicity, high potency and are also able to drive the immune response in the desired direction. Ideally, a vaccine would only consist of well-characterized, synthetic materials. This review summarizes the different approaches for the development of completely defined synthetic vaccines.
Zauner
W
W
Intercell AG, Vienna, Austria.
Lingnau
K
K
Mattner
F
F
von Gabain
A
A
Buschle
M
M
D000276:Adjuvants, Immunologic; D000818:Animals; D003140:Communicable Disease Control / Q000379:methods; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006801:Humans; D008081:Liposomes; D009838:Oligodeoxyribonucleotides / Q000276:immunology; D009842:Oligopeptides / Q000008:administration & dosage / Q000276:immunology*; D011136:Polysorbates; D013185:Squalene / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D018984:Epitopes, T-Lymphocyte; D008081:Liposomes; C089950:MF59 oil emulsion; D009838:Oligodeoxyribonucleotides; D009842:Oligopeptides; D011136:Polysorbates; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D013185:Squalene